|
| 37830403 | Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data. | Eur J Haematol | 2024 |
| 34856195 | Outcomes of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Tertiary Care Center. | Hematol Oncol Stem Cell Ther | 2023 |
| 37491877 | Prognostic implication of pre-transplant FEV<sub>1</sub> on long-term outcomes following allogeneic hematopoietic stem cell transplantation. | Eur J Haematol | 2023 |
| 37797719 | Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal Photopheresis to Best Available Therapy in Third-Line or Beyond Treatment for Chronic GvHD. | Transplant Cell Ther | 2023 |
| 37620424 | HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantation. | Bone Marrow Transplant | 2023 |
| 37999143 | Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study. | Curr Oncol | 2023 |
| 37582470 | Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. | Transplant Cell Ther | 2023 |
| 37581458 | A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes. | Hematol Oncol Stem Cell Ther | 2023 |
| 37579919 | Choosing Between Older Matched Sibling Donor and Younger Matched Unrelated Donor in Allogeneic Hematopoietic Cell Transplantation: Comparison of Clinical Outcomes in Acute Myeloid Leukemia and Myelodysplastic Syndrome. | Transplant Cell Ther | 2023 |
| 37734221 | Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure. | Leuk Res | 2023 |
| 37676349 | Weight loss post-allogeneic stem cell transplant is associated with increased transplant-related mortality. | Support Care Cancer | 2023 |
| 37040999 | Tumour lysis syndrome. | CMAJ | 2023 |
| 37437765 | Interaction Between High-Dose Intravenous Busulfan and Post-Transplantation Cyclophosphamide on Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplantation. | Transplant Cell Ther | 2023 |
| 37461810 | Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission. | Eur J Haematol | 2023 |
| 36820907 | Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience. | Ann Hematol | 2023 |
| 36655501 | Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation. | Clin Chem Lab Med | 2023 |
| 36526806 | Impact of hematopoietic cell transplant frailty scale on transplant outcome in adults. | Bone Marrow Transplant | 2023 |
| 36727396 | Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up. | Haematologica | 2023 |
| 34656808 | Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. | Transplant Cell Ther | 2022 |
| 35752740 | Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes. | Bone Marrow Transplant | 2022 |
| 35892015 | Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant. | Clin Kidney J | 2022 |
| 36051057 | The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. | EJHaem | 2022 |
| 35914727 | Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients. | Transplant Cell Ther | 2022 |
| 35100661 | Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma. | Eur J Haematol | 2022 |
| 34905239 | Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors. | Eur J Haematol | 2022 |
| 35139398 | Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. | Transplant Cell Ther | 2022 |
| 34866020 | Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients. | Clin Lymphoma Myeloma Leuk | 2022 |
| 34606661 | Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. | Eur J Haematol | 2022 |
| 32599663 | Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. | Eur J Haematol | 2021 |
| 33827366 | Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data. | Leuk Lymphoma | 2021 |
| 33684377 | Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use. | Hematol Oncol Stem Cell Ther | 2021 |
| 33767401 | Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. | Bone Marrow Transplant | 2021 |
| 33678592 | Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia. | Clin Lymphoma Myeloma Leuk | 2021 |
| 33710366 | Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. | Ann Hematol | 2021 |
| 34435547 | Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. | Leuk Lymphoma | 2021 |
| 34076909 | Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. | Eur J Haematol | 2021 |
| 33965185 | Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. | Transplant Cell Ther | 2021 |
| 34108675 | Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. | Bone Marrow Transplant | 2021 |
| 33049225 | Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. | Hematol Oncol Stem Cell Ther | 2021 |
| 33421199 | Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. | Eur J Haematol | 2021 |
| 33047394 | Prolactin, a potential biomarker for chronic GVHD activity. | Eur J Haematol | 2021 |
| 32606454 | Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. | Bone Marrow Transplant | 2021 |
| 32382774 | Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. | Ann Hematol | 2020 |
| 30706524 | Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML. | Eur J Haematol | 2019 |
| 28892201 | Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma. | Mol Carcinog | 2018 |
| 28135648 | Current approach to the treatment of chronic myeloid leukaemia. | Leuk Res | 2017 |
| 25415046 | NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. | Oncotarget | 2014 |
| 20048075 | Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. | Cancer Res | 2010 |
| 20495362 | The oncogenic and growth-suppressive functions of the integrin-linked kinase are distinguished by JNK1 expression in human cancer cells. | Cell Cycle | 2010 |
| 12444098 | The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis. | Hum Mol Genet | 2002 |